Core Viewpoint - The company, Xinwei Medical (心玮医疗-B), is experiencing significant stock price appreciation and is projecting substantial revenue growth for the fiscal year ending December 31, 2025, driven by new product launches and market share gains in the ischemic stroke segment [1] Group 1: Financial Performance - Xinwei Medical expects to achieve revenue between approximately RMB 400 million and RMB 410 million, representing a year-on-year increase of at least 43.9% [1] - The company anticipates a pre-tax profit of approximately RMB 80 million, marking a turnaround from previous losses [1] - Revenue growth is attributed to the launch of new products and technologies for ischemic stroke, increased market share, and effective cost control measures [1] Group 2: Product Development - The company announced that its self-expanding intracranial drug-eluting stent registration application has been accepted by the National Medical Products Administration [1] - This stent is designed for the treatment of intracranial atherosclerotic stenosis, providing support and patency to narrowed and obstructed lumens while effectively preventing in-stent restenosis [1] - Currently, there are no similar products approved for market globally, indicating that the company is at the forefront of this product development within the industry [1]
心玮医疗-B涨超12% 预计2025年除税前利润约8000万元 同比扭亏为盈